Myriad Genetics (MYGN) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Myriad Genetics (MYGN) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 44.3% versus a loss of 84.3%. Myriad Genetics is the larger company by market cap ($412.2 million vs $204.5 million), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | NNNN |
|---|---|---|
| Share price | $4.31 | $4.66 |
| Market cap | $412.25M | $204.53M |
| 1-day change | +2.62% | +0.87% |
| YTD return | -29.92% | -84.50% |
| 1-year return | -44.32% | -84.25% |
| 5-year return | -86.42% | — |
| P/E ratio (TTM) | — | 31.07 |
| EPS (TTM) | $-1.18 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.59 | $44.73 |
| 52-week low | $2.74 | $4.20 |
| Distance from 52-week high | -49.83% | -89.58% |
| Analyst consensus | hold | — |
| Avg. price target upside | -9.28% | — |
| Average volume | 2.04M | 146.84K |
| Shares outstanding | 95.65M | 43.89M |
| Employees | 2,700 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Myriad Genetics is about 2.0 times larger than Anbio Biotechnology by market value ($412.25M vs $204.53M).
- MYGN has outperformed NNNN by 39.9 percentage points over the past year.
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
MYGN vs NNNN FAQ
Which is bigger, Myriad Genetics or Anbio Biotechnology?
Myriad Genetics (MYGN) is larger, with a market capitalization of $412.25M compared with $204.53M for Anbio Biotechnology (NNNN).
Which stock has performed better over the past year, MYGN or NNNN?
MYGN returned -44.32% over the past 12 months, compared with -84.25% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and Anbio Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.